The Lucentis (ranibizumab, Genentech) biosimilar is currently known as Xlucane. Xbrane and Stada will finalize development of the biosimilar, with Xbrane providing the commercial supply. After regulatory approval, Bausch + Lomb will undertake marketing, sales and commercialization of the product in the U.S. and Canada.

“Through this agreement with Stada and Xbrane, we will be able to leverage our extensive expertise and heritage in the North American ophthalmic market,” Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in a press release. “We believe that, once approved, this biosimilar ranibizumab candidate will be an excellent addition to our comprehensive eye health portfolio and further deliver on our commitment of continuing to expand and improve upon our ophthalmic portfolio for our customers and their patients.”

According to the release, Bausch + Lomb will make a mid-single digit million upfront payment and further milestone payments after approval and launch of the product. Xbrane and Stada will also receive an equal share of gross profits from sales of the biosimilar.